Global Alzheimer’s Therapeutics Market is Expected to Reach USD 8.19 Billion By 2026 : Fior Markets
09 juil. 2019 07h57 HE
|
Fior Markets
New Jersey, NJ, July 09, 2019 (GLOBE NEWSWIRE) -- Fior Markets launched a study titled "Alzheimer’s Therapeutics Market by Drug Type (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor...
Alzheimer’s Therapeutics Market to Reach USD 12.43 Billion By 2026 | Reports And Data
02 mai 2019 12h00 HE
|
Reports And Data
Rising incidence of investment in biomarkers for drug development is the major factor influencing market growth. Market Size – USD 18.23 billion in 2018, Market Growth - CAGR of 4.6%, Market Trends...
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
01 août 2018 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes
15 sept. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
01 août 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update
28 juil. 2016 16h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
09 mai 2016 16h15 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
05 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
23 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
18 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...